Japanese Patients Tolerate Tirzepatide Much Better — And Diet May Be Why | Research

The takeaway

Japanese patients on tirzepatide had a remarkably low discontinuation rate of 1.3% compared to 6-10% in Western populations, possibly because traditional Japanese dietary patterns reduce gastrointestinal side effects.

1.3% vs 6-10%
Japanese patients discontinued tirzepatide at roughly one-fifth to one-eighth the rate of Western patients, with traditional Japanese dietary patterns as the proposed explanation

What the researchers found

Among 219 Japanese diabetes patients treated with tirzepatide in real-world clinical practice, the discontinuation rate due to gastrointestinal adverse events was approximately 1.3% — dramatically lower than the 6-10% rates reported in Western clinical trials.

Dietary questionnaire data revealed a key behavioral pattern: patients reported reduced appetite specifically for high-fat and high-calorie foods, while maintaining their consumption of traditional Japanese low-carbohydrate foods such as fish and lean meat. This selective dietary shift toward the lower-fat traditional Japanese diet may have reduced the gastrointestinal burden that causes many Western patients to discontinue treatment.

Why it matters

GI side effects are the biggest barrier to GLP-1 and dual agonist therapy adherence. If dietary patterns significantly influence tolerability, this opens a practical intervention: dietary counseling tailored to minimize GI side effects could help more patients stay on these effective drugs. The Japanese experience suggests that a lower-fat, fish-rich diet may be the key to tolerating incretin-based therapies.

How the study worked

Real-world observational study of 219 Japanese patients with diabetes treated with tirzepatide. Discontinuation rates were tracked and compared to published Western trial data (6-10%). Dietary questionnaires assessed changes in food preferences and consumption patterns during tirzepatide treatment.

What this study cannot tell us

This is a single-center observational study without a control group. The comparison to Western discontinuation rates (6-10%) is indirect, using published literature rather than a matched cohort. Genetic differences between Japanese and Western populations (body composition, metabolism, GI physiology) may also contribute and were not controlled for. Dietary questionnaires are subject to recall and social desirability bias. The sample size of 219 is modest.

How to read the evidence

This is a real-world observational study with dietary questionnaire data. While it provides an intriguing signal, the lack of a control group, indirect comparison to Western data, and potential genetic confounders limit causal conclusions. The finding is hypothesis-generating rather than definitive.

When this study was published

Published in 2025, this is a very current real-world study reflecting early post-marketing experience with tirzepatide in Japan. As tirzepatide use expands globally, more cross-cultural tolerability data will emerge.

The bigger picture

As GLP-1 and dual agonist prescriptions surge globally, drug tolerability has become a major practical challenge. Millions of patients worldwide start and stop these drugs due to GI side effects. This study introduces an important variable — dietary pattern — that has been largely overlooked in the tolerability conversation. If confirmed, dietary modification could become a standard adjunct to incretin therapy, potentially benefiting patients of all backgrounds.

Questions still open

Would Western patients on tirzepatide who adopt a lower-fat, Japanese-style diet also experience fewer GI side effects?
How much of the tolerability difference is due to diet versus genetic or metabolic differences between Japanese and Western populations?
Could proactive dietary counseling during GLP-1/GIP agonist initiation improve adherence globally?

Common questions

Why might Japanese diet reduce GI side effects from tirzepatide?

Tirzepatide slows stomach emptying and reduces appetite, which can cause nausea and vomiting — especially after high-fat meals that already sit heavy in the stomach. Traditional Japanese food tends to be lower in fat and richer in fish, vegetables, and lean protein. The study found that Japanese patients naturally reduced high-fat food intake while maintaining traditional eating patterns, which may have avoided the dietary triggers that worsen GI side effects.

Could changing my diet help me tolerate GLP-1 or GIP drugs better?

This study suggests it might. While not proven in a controlled trial, the data imply that eating smaller, lower-fat meals — rather than heavy, high-calorie foods — could reduce nausea and other GI side effects from drugs like tirzepatide, semaglutide, and similar medications. Many clinicians already advise eating smaller meals during the dose-escalation phase.

Read the original research

Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet.

Journal of health, population, and nutrition, 44(1), 429

View on PubMed ↗Publisher’s paper ↗

Citation

Hiraide, Takahiro; Suzuki, Yoshihiko; Yamamoto, Satoko; Yagihashi, Soroku; Sano, Motoaki. (2025). Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet.. Journal of health, population, and nutrition, 44(1), 429. https://doi.org/10.1186/s41043-025-01161-1